TG THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TG THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $85.00K, a 80.32% decline year-over-year.
- TG THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $763.00K, a 3533.33% increase year-over-year.
- TG THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $432.00K, a 220.00% increase year-over-year.
- TG THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $21.00K, a 110.00% increase year-over-year.
- TG THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.51M, a 65.32% increase from fiscal 2024.
- TG THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $914.00K, a 40.42% decline from fiscal 2023.
- TG THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.53M, a 162.67% increase from fiscal 2022.
- TG THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $584.00K, a 170.37% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $85.00K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $763.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $1.51M 10-K · filed 2026-02-27 | |
| 2025-06-30 | $432.00K 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $21.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $914.00K 10-K · filed 2026-02-27 | |
| 2024-09-30 | $199.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $135.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $10.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $1.53M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $420.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $751.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $363.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $584.00K 10-K · filed 2025-03-03 | |
| 2022-09-30 | $275.00K 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $135.00K 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $125.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $216.00K 10-K · filed 2024-02-29 | |
| 2021-09-30 | $50.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $38.00K 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $128.00K 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $146.00K 10-K · filed 2023-03-01 | |
| 2020-09-30 | $38.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $16.00K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $80.00K 10-Q · filed 2021-11-08 | |
| 2014-12-31 | $57.20K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $202.40K 10-K · filed 2015-03-16 |
| 2005-12-31 | $32.40K 10-Q · filed 2011-11-14 | |
| 2004-12-31 | $30.10K 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |